×
TransCode Therapeutics EBIT 2021-2024 | RNAZ
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
TransCode Therapeutics ebit from 2021 to 2024. Ebit can be defined as earnings before interest and taxes.
Historical Chart (TTM)
Quarterly
Quarterly - YOY Change
Annual
Annual % Change
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$95B
Zoetis (ZTS)
$66.3B
Takeda Pharmaceutical (TAK)
$46.8B
Daiichi Sankyo, - (DSNKY)
$41.7B
Summit Therapeutics (SMMT)
$18.2B
Sandoz Group AG (SDZNY)
$17.7B
Merck (MKKGY)
$17.2B
Astellas Pharma (ALPMY)
$16.9B
Shionogi (SGIOY)
$14.1B
United Therapeutics (UTHR)
$12.8B
Neurocrine Biosciences (NBIX)
$10B
IPSEN (IPSEY)
$8.6B
Orion OYJ (ORINY)
$8B
Madrigal Pharmaceuticals (MDGL)
$6.7B
Stevanato Group S.p.A (STVN)
$6.6B
Corcept Therapeutics (CORT)
$6.6B
Hikma Pharmaceuticals Plc (HKMPF)
$5.8B
Ono Pharmaceutical (OPHLF)
$5.5B
Grifols, S.A (GRFS)
$4.9B
Ionis Pharmaceuticals (IONS)
$4.5B
Soleno Therapeutics (SLNO)
$3.2B
Crinetics Pharmaceuticals (CRNX)
$2.8B
Catalyst Pharmaceuticals (CPRX)
$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.3B
Recursion Pharmaceuticals (RXRX)
$2.2B
Hypermarcas (HYPMY)
$2.1B
NewAmsterdam Pharma (NAMS)
$1.8B
Centessa Pharmaceuticals (CNTA)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.5B
Guardian Pharmacy Services (GRDN)
$1.5B